|
Pulmonology
Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion
Jaehee Lee, Deok Heon Lee, Ji Eun Park, Yong Hoon Lee, Sun Ha Choi, Hyewon Seo, Seung Soo Yoo, Shin Yup Lee, Seung-Ick Cha, Jae Yong Park, Chang Ho Kim
Korean J Intern Med. 2024;39(2):318-326. Published online February 14, 2024
Background/Aims: Epidermal growth factor receptor (EGFR) mutation is important in determining the treatment strategy for advanced lung cancer patients with malignant pleural effusion (MPE). Contrary to serum carcinoembryonic antigen (S-CEA) levels, the associations between pleural fluid CEA (PF-CEA)..
|
|
|
Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer
Seung Hun Jang, Dong Yoon Lee, Jihyeon Jeong, Won-Il Choi
Korean J Intern Med. 2022;37(4):811-820. Published online June 3, 2022
Background/Aims: The treatment of epidermal growth factor receptor (EGFR)-mutated lung cancer cases has shown remarkable development in the past two decades. However, there have been limited studies comparing the prognostic effects of EGFR-tyrosine kinase inhibitor (TKI) and other treatment modaliti..
|
|
|
Hemato-oncology
The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
Jin-Hyuk Choi, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Mi Sun Ahn, Young-Taek Oh, O kyu Noh, Se-Hyuk Kim, Tae Hoon Roh, Seung Soo Sheen
Korean J Intern Med. 2022;37(2):434-443. Published online February 16, 2022
Background/Aims: The optimal treatment (Tx) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) remains to be determined.
Methods: A retrospective review was conducted on 77 NSCLC patients with synchronous BM who underwent first-..
|
|
|
Pulmonology
Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma
Jae Kyeom Sim, Sang Mi Chung, Jong Hyun Choi, Jee Youn Oh, Seung Heon Lee, Je Hyeong Kim, Kyung Hoon Min, Gyu Young Hur, Jae Jeong Shim, Kyung Ho Kang, Bong Kyung Shin, Ju Han Lee, Sung Yong Lee
Korean J Intern Med. 2018;33(4):737-744. Published online February 20, 2018
Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis.
Me..
|
|
|
Hemato-oncology
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
Min Young Baek, Hee Kyung Ahn, Kyu Ree Park, Hwa-Sun Park, Shin Myung Kang, Inkeun Park, Young Saing Kim, Junshik Hong, Sun Jin Sym, Jinny Park, Jae Hoon Lee, Dong Bok Shin, Eun Kyung Cho
Korean J Intern Med. 2018;33(1):168-175. Published online April 20, 2016
Background/Aims: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status...
|
|
|
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Yong Won Choi, Jin-Hyuk Choi
Korean J Intern Med. 2017;32(3):422-428. Published online March 30, 2017
An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Many retrospective and prospective studi..
|
|
|
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small
cell lung cancer with activating epidermal growth factor receptor mutations
Sehhoon Park, Seongyeol Park, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Young Whan Kim, Dae Seog Heo
Korean J Intern Med. 2016;31(6):1140-1149. Published online March 28, 2016
Background/Aims: Pretreatment nutritional status is an important prognostic factor in patients treated with conventional cytotoxic chemotherapy. In the era of target therapies, its value is overlooked and has not been investigated. The aim of our study is to evaluate the value of nutritional status ..
|
|
|
